Insmed Inc Stock Probability Of Bankruptcy
| INSM Stock | USD 25.02 0.08 0.32% |
Insmed | Probability Of Bankruptcy |
Insmed Probability Of Bankruptcy Analysis
Insmed's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
| 2020 | 2021 | 2022 | 2023 (projected) | Interest Expense | 29.6M | 40.5M | 26.4M | 22.7M | Gross Profit | 124.5M | 144.3M | 190.2M | 157.1M |
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Insmed Probability Of Bankruptcy | Over 58% |
Most of Insmed's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Insmed Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Insmed probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Insmed odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Insmed Inc financial health.
Is Insmed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.29) | Revenue Per Share 2.043 | Quarterly Revenue Growth 0.167 | Return On Assets (0.36) | Return On Equity (14.53) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Insmed Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Insmed is extremely important. It helps to project a fair market value of Insmed Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Insmed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Insmed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Insmed's interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Insmed Inc has a Probability Of Bankruptcy of 58%. This is 33.98% higher than that of the Biotechnology sector and 5.76% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 45.62% lower than that of the firm.
Insmed Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Insmed's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Insmed could also be used in its relative valuation, which is a method of valuing Insmed by comparing valuation metrics of similar companies.Insmed is currently under evaluation in probability of bankruptcy category among related companies.
Insmed Main Bankruptcy Drivers
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 (projected) | ||
| Return on Average Assets | (0.62) | (0.58) | (0.47) | (0.37) | (0.39) | (0.43) | |
| Total Debt | 316.6M | 397.0M | 404.8M | 612.3M | 1.3B | 1.4B | |
| Total Liabilities | 396.3M | 480.6M | 520.3M | 833.0M | 1.6B | 1.7B | |
| Current Liabilities | 79.7M | 85.2M | 118.8M | 135.2M | 190.2M | 205.3M | |
| Total Assets | 604.6M | 742.3M | 796.2M | 1.2B | 1.7B | 1.8B | |
| Current Assets | 518.9M | 555.2M | 622.9M | 837.0M | 1.3B | 1.4B | |
| Net Cash Flow from Operations | (258.0M) | (250.6M) | (219.3M) | (363.3M) | (400.4M) | (411.0M) | |
| Weighted Average Shares | 76.9M | 84.6M | 97.6M | 112.1M | 123.0M | 106.1M | |
| Weighted Average Shares Diluted | 76.9M | 84.6M | 97.6M | 112.1M | 123.0M | 106.1M |
Insmed Fundamentals
| Return On Equity | -14.53 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (2.58) % | ||||
| Operating Margin | (1.75) % | ||||
| Current Valuation | 3.97 B | ||||
| Shares Outstanding | 143.06 M | ||||
| Shares Owned By Insiders | 1.29 % | ||||
| Shares Owned By Institutions | 98.71 % | ||||
| Number Of Shares Shorted | 14.17 M | ||||
| Price To Earning | (8.70) X | ||||
| Price To Book | 48.18 X | ||||
| Price To Sales | 10.89 X | ||||
| Revenue | 245.36 M | ||||
| Gross Profit | 190.23 M | ||||
| EBITDA | (458.21 M) | ||||
| Net Income | (481.53 M) | ||||
| Cash And Equivalents | 554.87 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 1.18 B | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | (2.02) X | ||||
| Cash Flow From Operations | (400.44 M) | ||||
| Short Ratio | 10.72 X | ||||
| Earnings Per Share | (5.29) X | ||||
| Target Price | 41.42 | ||||
| Number Of Employees | 736 | ||||
| Beta | 1.4 | ||||
| Market Capitalization | 3.59 B | ||||
| Total Asset | 1.66 B | ||||
| Retained Earnings | (2.7 B) | ||||
| Working Capital | 1.08 B | ||||
| Current Asset | 28.15 M | ||||
| Current Liabilities | 3.89 M | ||||
| Z Score | -0.43 | ||||
| Annual Yield | 0.014 % | ||||
| Net Asset | 1.66 B |
About Insmed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Insmed Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insmed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insmed Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. Insmed operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 613 people.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Insmed without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Insmed Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Insmed Piotroski F Score and Insmed Altman Z Score analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Insmed Stock analysis
When running Insmed's price analysis, check to measure Insmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insmed is operating at the current time. Most of Insmed's value examination focuses on studying past and present price action to predict the probability of Insmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insmed's price. Additionally, you may evaluate how the addition of Insmed to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Insmed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.29) | Revenue Per Share 2.043 | Quarterly Revenue Growth 0.167 | Return On Assets (0.36) | Return On Equity (14.53) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.